{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:49:48Z","timestamp":1783748988995,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Pfizer BioNTech COVID-19 vaccine was the first to receive emergency authorization and approval from the FDA. Therefore, it is preferred by most recipients; however, many people are concerned about the vaccine\u2019s side effects. At the time of the study, December 2021, Palestine lacked a national reporting system for monitoring adverse vaccine effects. Therefore, this study investigates the post-vaccine adverse events following the Pfizer\/BioNTech COVID-19 Vaccine administration in Palestine and identifies the occurrence, extent, and severity among university staff, employees, and students at Birzeit University.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A questionnaire-based retrospective cross-sectional study was conducted using a university website (Ritaj), social media platforms (e.g., Facebook and Telegram), and in-person interviews. The Chi-square, Fisher\u2019s exact, and McNemar\u2019s tests were used to investigate significant relationships. Data were analyzed using SPSS version 22.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 1137 participants completed the questionnaire, 33.2% were males, and the mean age was 21.163\u00a0years. All participants received at least one dose of the Pfizer-BioNTech COVID-19 vaccine. Approximately one-third of participants reported no adverse effects after receiving the first, second, or third doses (34%, 33.6%, and 32.5%, respectively). The most commonly reported adverse events were fever, chills, headache, fatigue, pain and swelling at the injection site, muscle pain, and joint pain. Allergic reactions were reported by 12.7% of the participants; furthermore, participants with a history of allergy or anaphylaxis before vaccination had a significantly higher tendency for post-vaccination allergic reactions. Eight participants reported rare side effects, including 7 (0.6%) cases of thrombocytopenia and one (0.1%) case of myocarditis. Males aged less than 20\u00a0years and smokers were significantly less likely to complain of adverse events. The number of reported side effects was significantly higher after the second vaccine dose than after the first dose. Finally, participants infected with COVID-19 before vaccination was significantly associated with side effects such as fever, chills, shortness of breath, and persistent cough.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this study, the most common\u00a0post- BNT162b2 Vaccination reported self-limiting side effects similar to those reported by Pfizer\/BioNTech Company. However, higher rates of allergic reactions were reported in this sample. Rare side effects, such as thrombocytopenia and myocarditis, were reported by 8 participants. COVID vaccines have been developed at an accelerated pace, and vaccine safety is a top priority; therefore, standard monitoring through a national adverse event reporting system is necessary for safety assurance. Continuous monitoring and long-term studies are required to ensure vaccine safety.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07974-3","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:04:24Z","timestamp":1672920264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Side effects of Pfizer\/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community"],"prefix":"10.1186","volume":"23","author":[{"given":"Abdallah Damin","family":"Abukhalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sireen Sultan","family":"Shatat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya Riyad","family":"Abushehadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni\u2019meh","family":"Al-Shami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani A.","family":"Naseef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Rabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"7974_CR1","unstructured":"Dashboard WCC-. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. 2022. https:\/\/covid19.who.int\/."},{"issue":"12","key":"7974_CR2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078\u201390.","journal-title":"N Engl J Med"},{"key":"7974_CR3","unstructured":"FDA. Vaccines and Related Biological Products Advisory Committee Meeting FDA Briefing Document Application for licensure of a booster dose for COMIRNATY (COVID-19 Vaccine, mRNA). 2021. https:\/\/www.fda.gov\/media\/152176\/download (accessed May 22 2022)."},{"issue":"44","key":"7974_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","volume":"70","author":"S Mbaeyi","year":"2021","unstructured":"Mbaeyi S, Oliver SE, Collins JP, et al. The advisory committee on immunization practices\u2019 interim recommendations for additional primary and booster doses of COVID-19 vaccines\u2014United States, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1545\u201352.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"7974_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.15585\/mmwr.mm7109e2","volume":"71","author":"AM Hause","year":"2022","unstructured":"Hause AM, Baggs J, Marquez P, et al. Safety monitoring of COVID-19 vaccine booster doses among persons aged 12\u201317 years\u2014United States, December 9, 2021\u2013February 20, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(9):347\u201351.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7974_CR6","unstructured":"CDC. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events 2022. https:\/\/www.cdc.gov\/vaccines\/COVID-19\/info-by-product\/pfizer\/reactogenicity.html."},{"key":"7974_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108906","volume":"109","author":"H Kouhpayeh","year":"2022","unstructured":"Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: a systematic review and meta-analysis. Int Immunopharmacol. 2022;109: 108906.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"7974_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10900-021-01039-3","volume":"47","author":"G Ripabelli","year":"2022","unstructured":"Ripabelli G, Tamburro M, Buccieri N, et al. Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNTech, Comirnaty): a cross-sectional study. J Community Health. 2022;47(2):211\u201325.","journal-title":"J Community Health"},{"issue":"14","key":"7974_CR9","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","volume":"326","author":"NP Klein","year":"2021","unstructured":"Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390.","journal-title":"JAMA"},{"issue":"8","key":"7974_CR10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.vaccine.2018.01.018","volume":"36","author":"S Tafuri","year":"2018","unstructured":"Tafuri S, Fortunato F, Gallone MS, et al. Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy). Vaccine. 2018;36(8):1072\u20137.","journal-title":"Vaccine"},{"key":"7974_CR11","unstructured":"Unicef. Arrival of first wave consignment of COVAX COVID-19 vaccine doses to the State of Palestine. 2021. https:\/\/www.unicef.org\/press-releases\/arrival-first-wave-consignment-covax-COVID-19-vaccine-doses-state-palestine."},{"key":"7974_CR12","unstructured":"News.Google.Com. Coronavirus (COVID-19) 2022. https:\/\/news.google.com\/covid19\/map?hl=en-US&state=7&gl=US&ceid=US%3Aen&mid=%2Fm%2F01k0p4."},{"key":"7974_CR13","unstructured":"(WHO) WHO. COVID-19 vaccines: safety surveillance manual\u2014Establishing surveillance systems in countries. 2020. https:\/\/www.who.int\/publications\/m\/item\/WHO-MHP-RPQ-PVG-2021.12."},{"issue":"1","key":"7974_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/vaccines10010018","volume":"10","author":"MO Elgendy","year":"2021","unstructured":"Elgendy MO, El-Gendy AO, Alzarea AI, et al. SARS-CoV-2 post vaccinated adverse effects and efficacy in the Egyptian population. Vaccines. 2021;10(1):18.","journal-title":"Vaccines"},{"issue":"3","key":"7974_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/vaccines10030366","volume":"10","author":"MM Hatmal","year":"2022","unstructured":"Hatmal MM, Al-Hatamleh MAI, Olaimat AN, et al. Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors. Vaccines (Basel). 2022;10(3):366.","journal-title":"Vaccines (Basel)"},{"key":"7974_CR16","unstructured":"WHO. Global Manual On Surveillance Of Adverse Events Following Immunization. 2022. https:\/\/www.who.int\/publications\/i\/item\/10665206144 (accessed Dec 16 2022)."},{"key":"7974_CR17","unstructured":"Pfizer. FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS) 2020. www.cvdvaccine.com. (accessed May 22 2022)."},{"key":"7974_CR18","unstructured":"Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC.; 2022."},{"issue":"3","key":"7974_CR19","volume":"14","author":"IM Dighriri","year":"2022","unstructured":"Dighriri IM, Alhusayni KM, Mobarki AY, et al. Pfizer-BioNTech COVID-19 vaccine (BNT162b2) side effects: a systematic review. Cureus. 2022;14(3): e23526.","journal-title":"Cureus"},{"issue":"4","key":"7974_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","volume":"36","author":"RJ Kaur","year":"2021","unstructured":"Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427\u201339.","journal-title":"Indian J Clin Biochem"},{"issue":"5","key":"7974_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s10900-022-01112-5","volume":"47","author":"M Tamburro","year":"2022","unstructured":"Tamburro M, Ripabelli G, D\u2019Amico A, et al. A cross-sectional study of untoward reactions following homologous and heterologous COVID-19 booster immunizations in recipients seventeen years of age and older. J Community Health. 2022;47(5):814\u201321.","journal-title":"J Community Health"},{"key":"7974_CR22","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2147\/PPA.S330689","volume":"15","author":"M Adam","year":"2021","unstructured":"Adam M, Gameraddin M, Alelyani M, et al. Evaluation of post-vaccination symptoms of two common COVID-19 vaccines used in Abha, Aseer Region, Kingdom of Saudi Arabia. Patient Prefer Adherence. 2021;15:1963\u201370.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"7974_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257668","volume":"16","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi M, Higa Y, Esaki A, Nabeshima Y, Nakazono A. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects? PLoS ONE. 2021;16(9): e0257668.","journal-title":"PLoS ONE"},{"issue":"10","key":"7974_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jamacardio.2021.2821","volume":"6","author":"DK Shay","year":"2021","unstructured":"Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021;6(10):1115\u20137.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"7974_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18512","volume":"5","author":"ES Weintraub","year":"2022","unstructured":"Weintraub ES, Oster ME, Klein NP. Myocarditis or pericarditis following mRNA COVID-19 vaccination. JAMA Netw Open. 2022;5(6): e2218512.","journal-title":"JAMA Netw Open"},{"key":"7974_CR26","doi-asserted-by":"crossref","unstructured":"Heidecker B, Dagan N, Balicer R, et al. Myocarditis following <scp>COVID<\/scp> \u201019 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the Eu. Eur J Heart Failure 2022.","DOI":"10.1002\/ejhf.2669"},{"key":"7974_CR27","doi-asserted-by":"crossref","unstructured":"Straus W, Urdaneta V, Esposito DB, et al. Myocarditis After mRNA-1273 vaccination: a population-based analysis of 151 million vaccine recipients worldwide. Cold Spring Harbor Laboratory; 2021.","DOI":"10.1101\/2021.11.11.21265536"},{"key":"7974_CR28","unstructured":"NewsGP. TGA releases updated COVID booster safety data. 2022. https:\/\/www1.racgp.org.au\/newsgp\/clinical\/tga-releases-updated-covid-booster-safety-data (accessed June 11 2022)."},{"issue":"12","key":"7974_CR29","doi-asserted-by":"publisher","first-page":"E467","DOI":"10.1002\/dc.24863","volume":"49","author":"NJH Tan","year":"2021","unstructured":"Tan NJH, Tay KXJ, Wong SBJ, Nga ME. COVID-19 post-vaccination lymphadenopathy: report of cytological findings from fine needle aspiration biopsy. Diagn Cytopathol. 2021;49(12):E467\u201370.","journal-title":"Diagn Cytopathol"},{"issue":"27","key":"7974_CR30","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"7974_CR31","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.21873\/invivo.12921","volume":"36","author":"N Yoshimoto","year":"2022","unstructured":"Yoshimoto N, Yanagi A, Takayama S, et al. Axillary lymph node swelling after COVID-19 booster vaccination: Japanese case report and literature review. In Vivo. 2022;36(4):1977\u201381.","journal-title":"In Vivo"},{"key":"7974_CR32","doi-asserted-by":"crossref","unstructured":"Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm 2021.","DOI":"10.1136\/ejhpharm-2021-002933"},{"key":"7974_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/IJGM.S310497","volume":"14","author":"NA El-Shitany","year":"2021","unstructured":"El-Shitany NA, Harakeh S, Badr-Eldin SM, et al. Minor to moderate side effects of pfizer-BioNTech COVID-19 vaccine among saudi residents: a retrospective cross-sectional study. Int J Gen Med. 2021;14:1389\u2013401.","journal-title":"Int J Gen Med"},{"issue":"6","key":"7974_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/vaccines9060553","volume":"9","author":"M Nittner-Marszalska","year":"2021","unstructured":"Nittner-Marszalska M, Rosiek-Biegus M, Kope\u0107 A, et al. Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals. Vaccines. 2021;9(6):553.","journal-title":"Vaccines"},{"issue":"10","key":"7974_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.31034","volume":"4","author":"L Li","year":"2021","unstructured":"Li L, Robinson LB, Patel R, et al. Association of self-reported high-risk allergy history with allergy symptoms after COVID-19 vaccination. JAMA Netw Open. 2021;4(10): e2131034.","journal-title":"JAMA Netw Open"},{"key":"7974_CR36","unstructured":"University B. Facts & Figures 2020\u20132021 2022. https:\/\/www.birzeit.edu\/en\/about\/facts\/2020-2021-0."},{"issue":"51","key":"7974_CR37","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1016\/j.vaccine.2013.09.066","volume":"31","author":"NA Halsey","year":"2013","unstructured":"Halsey NA, Griffioen M, Dreskin SC, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine. 2013;31(51):6107\u201312.","journal-title":"Vaccine"},{"issue":"10","key":"7974_CR38","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626\u201338.","journal-title":"Nat Rev Immunol"},{"issue":"7837","key":"7974_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","volume":"588","author":"T Takahashi","year":"2020","unstructured":"Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315\u201320.","journal-title":"Nature"},{"issue":"8","key":"7974_CR40","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/vaccines9080911","volume":"9","author":"MA Hoffmann","year":"2021","unstructured":"Hoffmann MA, Wieler HJ, Enders P, Buchholz HG, Plachter B. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany. Vaccines (Basel). 2021;9(8):911.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"7974_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines10020303","volume":"10","author":"P Ferrara","year":"2022","unstructured":"Ferrara P, Gianfredi V, Tomaselli V, Polosa R. The effect of smoking on humoral response to COVID-19 vaccines: a systematic review of epidemiological studies. Vaccines (Basel). 2022;10(2):303.","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"7974_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","volume":"19","author":"KL O'Brien","year":"2019","unstructured":"O\u2019Brien KL, Finlay DK. Immunometabolism and natural killer cell responses. Nat Rev Immunol. 2019;19(5):282\u201390.","journal-title":"Nat Rev Immunol"},{"key":"7974_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.760047","volume":"8","author":"AN Alghamdi","year":"2021","unstructured":"Alghamdi AN, Alotaibi MI, Alqahtani AS, Al Aboud D, Abdel-Moneim AS. BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination side-effects among Saudi vaccinees. Front Med (Lausanne). 2021;8: 760047.","journal-title":"Front Med (Lausanne)"},{"key":"7974_CR44","unstructured":"CDC. COVID-19 Vaccine Training Modules. 2022. https:\/\/www2.cdc.gov\/vaccines\/ed\/covid19\/pfizer\/20000.asp."},{"issue":"10","key":"7974_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/2165079919875161","volume":"67","author":"M Shahbaz","year":"2019","unstructured":"Shahbaz M, Blanc PD, Domeracki SJ, Guntur S. Shoulder injury related to vaccine administration (SIRVA): an occupational case report. Workplace Health Saf. 2019;67(10):501\u20135.","journal-title":"Workplace Health Saf"},{"issue":"2","key":"7974_CR46","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1503\/cmaj.211162","volume":"194","author":"JCK Chow","year":"2022","unstructured":"Chow JCK, Koles SL, Bois AJ. Shoulder injury related to SARS-CoV-2 vaccine administration. CMAJ. 2022;194(2):E46\u20139.","journal-title":"CMAJ"},{"key":"7974_CR47","unstructured":"Roberts L. AstraZeneca and Pfizer COVID vaccine shots lead to missed work days, survey reveals\u2014ABC News. 2021. https:\/\/www.abc.net.au\/news\/health\/2021-06-17\/side-effect-astra-pfizer-vaccine-australia-safety-data\/100202616."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07974-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07974-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07974-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T03:03:50Z","timestamp":1673233430000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07974-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7974"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07974-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"16 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants were given a brief introduction to the study's objectives and were asked to provide their informed consent before completing the questionnaire. This consent procedure was approved by the Ethics Committee of the Research Ethics Committee at the Faculty of Pharmacy, Nursing, and Health Professions, Birzeit University (reference number BZU-PNH-2103). The Ethics Committee of the Research Ethics Committee at the Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, approved this study. [Approval number BZU-PNH-2103]. Participation in the study was voluntary, and participants had the right to withdraw at any time. Personal information was not collected, and the participants\u2019 identities remained unknown. All collected information was used for the research purpose. The research was performed following the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}